EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression

Guang-Liang Chen iD, Yanjing Guo, Xin Liu iD, Ya'nan Yang, Youzhou Sang, Xueguan Lu, Si Sun, Xiao Shi iD, Yan Zhang, Tong-Zhen Chen, Ning Qu, Duo Wen und 9 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-26-00671 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Guang-Liang Chen und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Salivary Gland Neoplasms, Trastuzumab, Biomarkers, Tumor. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Systemic treatment options for advanced salivary gland carcinoma (SGC) are limited, and prospective data for human epidermal growth factor receptor 2 (HER2)–directed therapy remain sparse, particularly in HER2-low disease. We evaluated trastuzumab rezetecan (SHR-A1811), a HER2-directed antibody-drug conjugate, in prospectively defined HER2-high and HER2-low cohorts. PATIENTS AND METHODS In this phase II trial, patients with unresectable locally advanced or recurrent/metastatic SGC were enrolled in separate HER2-high (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+) and HER2-low (IHC 1+ or IHC 2+/ISH–) cohorts. Each cohort was independently evaluated using Simon's optimal two-stage design. SHR-A1811 was administered intravenously once every 3 weeks at a recommended starting dose of 4.8 mg/kg. The primary end point was confirmed objective response rate (ORR) per RECIST version 1.1. RESULTS Forty-six patients were enrolled and treated, including 24 in the HER2-high cohort and 22 in the HER2-low cohort. The median follow-up was 21.9 months (95% CI, 16.9 to 26.9) and 11.3 months (95% CI, 6.9 to 15.7), respectively. The confirmed ORR was 91.7% (95% CI, 73.0 to 99.0), including four complete responses, in the HER2-high cohort and 45.5% (95% CI, 24.4 to 67.8) in the HER2-low cohort. Median progression-free survival (PFS) and overall survival (OS) were not reached in the HER2-high cohort. In the HER2-low cohort, the median PFS was 12.7 months and the median OS was 21.3 months. Grade 3 or higher treatment-related adverse events occurred in 41.3% of patients, most commonly neutrophil count decreased (32.6%). Interstitial lung disease occurred in 6.5% of patients, all grade 1. No treatment-related deaths occurred. CONCLUSION SHR-A1811 showed high antitumor activity in HER2-high SGC and promising activity in HER2-low SGC, with a manageable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesSalivary Gland NeoplasmsTrastuzumabBiomarkers, TumorAntibodies, Monoclonal, HumanizedImmunoconjugatesAntineoplastic Agents, ImmunologicalHumansFemaleMiddle AgedAgedAdultMaleAged, 80 and overProgression-Free SurvivalCamptothecin

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabERBB2 protein, humanBiomarkers, TumorAntibodies, Monoclonal, Humanizedtrastuzumab deruxtecanImmunoconjugatesAntineoplastic Agents, ImmunologicalCamptothecin

Autor:innen und Institutionen

  • Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

ORCID-Profile: Guang-Liang Chen, Xin Liu, Xiao Shi, Shu Dong, Yu Wang, Chaosu Hu, Dongmei Ji

Zitieren

APA

Chen, G. L., Guo, Y., Liu, X., Yang, Y., Sang, Y., Lu, X., Sun, S., Shi, X., Zhang, Y., Chen, T. Z., Qu, N., Wen, D., Niu, X. S., Dong, S., Wang, Y., Wang, Y., Wang, J., Zhang, L., Hu, C., …, & Ji, D. (2026). Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00671

Vancouver

Chen GL, Guo Y, Liu X, Yang Y, Sang Y, Lu X, et al. Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00671

BibTeX
@article{Chen2026,
  author = {Chen, Guang-Liang and Guo, Yanjing and Liu, Xin and Yang, Ya'nan and Sang, Youzhou and Lu, Xueguan and Sun, Si and Shi, Xiao and Zhang, Yan and Chen, Tong-Zhen and Qu, Ning and Wen, Duo and Niu, Xiao-Shuang and Dong, Shu and Wang, Yu and Wang, Yulong and Wang, Jiachen and Zhang, Lu and Hu, Chaosu and Ji, Qinghai and Ji, Dongmei},
  title = {Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-26-00671}
}
Kostenlos starten →